journal
MENU ▼
Read by QxMD icon Read
search

CNS Oncology

journal
https://www.readbyqxmd.com/read/28718326/cns-anticancer-drug-discovery-and-development-2016-conference-insights
#1
Victor A Levin, Lauren E Abrey, Timothy P Heffron, Peter J Tonge, Arvin C Dar, William A Weiss, James M Gallo
CNS Anticancer Drug Discovery and Development November 2016, AZ, USA The 2016 second CNS Anticancer Drug Discovery and Development Conference addressed diverse viewpoints about why new drug discovery/development focused on CNS cancers has been sorely lacking. Despite more than 70,000 individuals in the USA being diagnosed with a primary brain malignancy and 151,669-286,486 suffering from metastatic CNS cancer, in 1999, temozolomide was the last drug approved by the US FDA as an anticancer agent for high-grade gliomas...
July 18, 2017: CNS Oncology
https://www.readbyqxmd.com/read/28718323/modern-approaches-to-the-management-of-metastatic-epidural-spinal-cord-compression
#2
Zain A Husain, Arjun Sahgal, Eric L Chang, Pejman Jabehdar Maralani, Charlotte D Kubicky, Kristin J Redmond, Charles Fisher, Ilya Laufer, Simon S Lo
Metastatic epidural spinal cord compression (MESCC) is an oncologic emergency requiring prompt treatment to maximize neurologic function, ambulatory function and local control. Traditionally, options for MESCC included external beam radiation therapy with or without surgery. Surgery has usually been reserved for the patient with optimal performance status, single level MESCC or mechanical instability. Advances in external beam radiation therapy such as the development of stereotactic body radiation therapy have allowed for the delivery of high-dose radiation, allowing for both long-term pain and local control...
July 18, 2017: CNS Oncology
https://www.readbyqxmd.com/read/28718316/predictors-of-complications-and-readmission-following-spinal-stereotactic-radiosurgery
#3
Daniel Lubelski, Joseph E Tanenbaum, Taylor E Purvis, Thomas T Bomberger, Courtney Rory Goodwin, Ilya Laufer, Daniel M Sciubba
AIM: to identify preoperative factors associated with morbidity/mortality, hospital length of stay (LOS), 30-day readmission and operation rates following spinal stereotactic radiosurgery (SRS) for spinal tumors. METHODS: The American College of Surgeons National Quality Improvement Program was queried from 2012 to 2014 to identify patients undergoing SRS for spinal tumors. Logistic regression was performed to identify predictors. RESULTS: 2714 patients were identified; 6...
July 18, 2017: CNS Oncology
https://www.readbyqxmd.com/read/28718312/gbm-skin-metastasis-a-case-report-and-review-of-the-literature
#4
Gary D Lewis, Andreana L Rivera, Ivo W Tremont-Lukats, Leomar Y Ballester-Fuentes, Yi Jonathan Zhang, Bin S Teh
Glioblastoma (GBM) is the most common type of malignant tumor found in the brain, and acts very aggressively by quickly and diffusely infiltrating the surrounding brain parenchyma. Despite its aggressive nature, GBM is rarely found to spread extracranially and develop distant metastases. The most common sites of these rare metastases are the lungs, pleura and cervical lymph nodes. There are also a few case reports of skin metastasis. We present the clinical, imaging and pathologic features of a case of a GBM with metastasis to the soft tissue scar and skin near the original craniotomy site...
July 18, 2017: CNS Oncology
https://www.readbyqxmd.com/read/28718307/late-post-treatment-radiographic-changes-3-years-following-chemoradiation-for-glioma-the-importance-of-histopathology
#5
Joao R Galante, Fausto Rodriguez, Stuart A Grossman, Roy E Strowd
Treatment-related changes can mimic brain tumor progression both clinically and radiographically. Distinguishing these two entities represents a major challenge in neuro-oncology. No single imaging modality is capable of reliably achieving such distinction. While histopathology remains the gold standard, definitive pathological criteria are also lacking which can further complicate such cases. We report a patient with high-grade glioma who, after initially presenting with histopathologically confirmed pseudoprogression 10 months following treatment, re-presented 3 years following concurrent chemoradiation with clinical and radiographic changes that were most consistent with progressive disease but for which histopathology revealed treatment effects without active glioma...
July 18, 2017: CNS Oncology
https://www.readbyqxmd.com/read/28718306/our-panel-of-experts-highlights-the-most-important-research-articles-across-the-spectrum-of-topics-relevant-to-the-field-of-cns-oncology
#6
Larry Junck, Maura Massimino
No abstract text is available yet for this article.
July 18, 2017: CNS Oncology
https://www.readbyqxmd.com/read/28718305/outcome-evaluation-of-patients-with-newly-diagnosed-anaplastic-gliomas-treated-in-a-single-institution
#7
Federico Pessina, Pierina Navarria, Luca Cozzi, Stefano Tomatis, Elena Clerici, Anna Maria Ascolese, Matteo Simonelli, Matteo Perrino, Marco Riva, Marco Rossi, Roberta Rudà, Armando Santoro, Lorenzo Bello, Marta Scorsetti
AIM: To evaluate the outcome of newly diagnosed anaplastic glioma patients treated in our institution in relation to the 2016 WHO classification suggestions. METHODS: This retrospective study included patients who underwent surgery plus adjuvant chemotherapy alone or concomitant and adjuvant chemoradiotherapy. Response was recorded using the Response Assessment in Neuro-Oncology criteria. RESULTS: 123 patients were analyzed. The median progression-free survival time and the 2, 3 and 5 years progression-free survival rate were 27 months, 65...
July 18, 2017: CNS Oncology
https://www.readbyqxmd.com/read/28718304/the-role-of-surgery-in-low-grade-gliomas-do-timing-and-extent-of-resection-matter
#8
Hugues Duffau
Hugues Duffau is a Professor and Chairman of the Neurosurgery Department in the Montpellier University Medical Center and Head of the INSERM 1051 Team "plasticity of the central nervous system, human stem cells and glial tumors" at the Institute for Neurosciences of Montpellier (France). He is an expert in the awake cognitive neurosurgery of slow-growing brain tumors, such as low-grade gliomas, a routine which he has developed since 20 years. His fundamental approach is centered on the concepts of the brain connectomics and neuroplasticity, breaking with the traditional localizationist view of cerebral processing...
July 18, 2017: CNS Oncology
https://www.readbyqxmd.com/read/28399638/tumor-treating-fields-plus-chemotherapy-versus-chemotherapy-alone-for-glioblastoma-at-first-recurrence-a-post-hoc-analysis-of-the-ef-14-trial
#9
Santosh Kesari, Zvi Ram
BACKGROUND: This post hoc analysis of the EF-14 trial (NCT00916409) of tumor-treating fields (TTFields) plus temozolomide versus temozolomide alone in newly diagnosed glioblastoma compared the efficacy of TTFields plus chemotherapy (physician's choice) versus chemotherapy alone after first recurrence. METHODS: Patients on TTFields plus temozolomide continued TTFields plus second-line chemotherapy after first recurrence. Some patients on temozolomide alone crossed over after approval of TTFields for recurrent GBM...
April 12, 2017: CNS Oncology
https://www.readbyqxmd.com/read/28530445/gamma-knife-treatment-of-recurrent-cns-metastases-of-pancreatic-origin-a-case-report-and-review-of-the-literature
#10
Subha Perni, Tony J Wang, Jerry Lesser, Christopher Mandigo, Steven R Isaacson, David P Horowitz
Brain metastases (BM) of pancreatic origin are extremely rare. We review the literature around BM of pancreatic origin and describe a 38-year-old woman who developed BM 10 months after pancreaticoduodenectomy for treatment of pancreatic adenocarcinoma. She underwent resection and fractionated stereotactic radiotherapy followed by re-resection and Gamma Knife radiosurgery (GKRS) when the lesion recurred. She then developed two new BM, and was treated with GKRS. The patient is alive without progression 38 months after her most recent GKRS...
April 2017: CNS Oncology
https://www.readbyqxmd.com/read/28425773/prognostic-value-of-pre-and-post-treatment-health-related-quality-of-life-in-predicting-survival-of-patients-with-brain-metastases
#11
Erin Wong, Leigha Rowbottom, May Tsao, Liying Zhang, Rachel McDonald, Cyril Danjoux, Elizabeth Barnes, Stephanie Chan, Edward Chow
AIM: The present study aimed to determine the prognostic survival value of pretreatment health-related quality of life (HRQOL) and changes in HRQOL following whole-brain radiation treatment in patients with brain metastases. METHODS: Patients who were treated with whole-brain radiation treatment and completed HRQOL questionnaires were included. Univariate and multivariate Cox proportional hazard models of overall survival (OS) were conducted for overall HRQOL and domain scores...
April 2017: CNS Oncology
https://www.readbyqxmd.com/read/28425771/review-of-stereotactic-radiosurgery-for-intradural-spine-tumors
#12
Taylor E Purvis, C Rory Goodwin, Daniel Lubelski, Ilya Laufer, Daniel M Sciubba
Stereotactic radiosurgery (SRS) has become an increasingly popular treatment modality for spinal tumors due to its noninvasive and targeted approach. Whether SRS has the promise of relieving pretreatment symptoms and providing local tumor control for patients with intradural spine tumors is still debated. This review explores the current literature on SRS treatment for both metastatic and benign intradural tumors, with a focus on differential use for intramedullary and intradural extramedullary neoplasms. Although mortality rates from underlying malignant disease remain high, SRS may benefit patients with spinal metastatic lesions...
April 2017: CNS Oncology
https://www.readbyqxmd.com/read/28425764/braf-v600e-mutant-papillary-craniopharyngioma-dramatically-responds-to-combination-braf-and-mek-inhibitors
#13
Ashley Roque, Yazmin Odia
We present a patient with BRAF-V600E mutant papillary craniopharyngioma successfully treated with combination BRAF (dabrafenib 150 mg twice daily) and MEK (trametinib 2 mg daily) inhibitors after her unresectable tumor proved refractory to radiation. Serial brain MRIs and PET revealed marked tumor reduction with gradual neurological improvement and permanent panhypopituitarism.
April 2017: CNS Oncology
https://www.readbyqxmd.com/read/28425763/our-panel-of-experts-highlights-the-most-important-research-articles-across-the-spectrum-of-topics-relevant-to-the-field-of-cns-oncology
#14
Larry Junck, Maura Massimino
Expert panel: Larry Junck, University of Michigan Health System, MI, USA; Maura Massimino, Fondazione Istituto di Ricovero & Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy.
April 2017: CNS Oncology
https://www.readbyqxmd.com/read/28425761/adult-pilocytic-astrocytoma-of-conus-medullaris-clinical-considerations-and-review-of-the-literature
#15
José Pedro Lavrador, Edson Oliveira, José Pimentel, Sérgio Livraghi
Astrocytomas are responsible for 30% of all primitive intramedullary tumors with cervicothoracic predominance. However, only about one hundred cases of intramedullary pilocytic astrocytomas were described. The authors described the case of a 69 year-old patient presenting with a broad-base gait, bilateral pain and dysesthesia of inferior limbs with a diagnosis of an intra-axial cystic lesion centered to the conus medullaris, diagnosed as pilocytic astrocytoma of conus medullaris (PACM) after surgery. To the best of our knowledge, only two previous reports concerning PACM were made...
April 2017: CNS Oncology
https://www.readbyqxmd.com/read/28425756/cns-hemangioblastomatosis-in-a-patient-without-von-hippel-lindau-disease
#16
Arie Franco, Peter Pytel, Rimas V Lukas, Rupa Chennamaneni, John M Collins
We report on a case of disseminated CNS hemangioblastoma, also referred to as hemangioblastomatosis, involving the supratentorial compartment and the entire spine. The patient presented with new onset headache, gait difficulties and memory deficits many years following resection of a hemangioblastoma from the cerebellum. The patient's family history was negative for von Hippel-Lindau (VHL) disease, and his personal history was negative for any additional VHL-defining lesions. Imaging revealed extensive dural caking and nodularity both supratentorially and in the spine, along with scattered parenchymal tumors showing a more typical appearance for hemangioblastoma...
April 2017: CNS Oncology
https://www.readbyqxmd.com/read/28425754/immunotherapy-and-targeted-therapy-in-brain-metastases-emerging-options-in-precision-medicine
#17
Tyler Lazaro, Priscilla K Brastianos
Brain metastases (BM) continue to represent an unmet clinical need in oncology. Immunotherapy and targeted therapy hold great promise in the treatment of BM. Emerging data are confirming the activity of these agents in patients with BM. Genomic studies have confirmed that clinically actionable mutations are present in BM and they can be used in clinical studies to link targeted therapies with their genetic targets. Furthermore, as molecular signatures associated with sensitivity and resistance to immunotherapies are developed, we will better be able to select BM patients who will most benefit from these therapies...
April 2017: CNS Oncology
https://www.readbyqxmd.com/read/28303729/case-of-glioblastoma-patient-treated-with-tumor-treating-fields-therapy-at-recurrence-degenerating-to-sarcoma
#18
Pejman Majd, Daniel E O'Connell, Ronald C Kim, Daniela A Bota, Jose A Carrillo
Optune(®) treatment is a US FDA-approved treatment for glioblastoma (GBM) that employs alternating electric fields. Tumor treating field (TTF) therapy can exert its effects on GBM via cell cycle mitosis disruption and cytokinesis. We describe a patient with recurrent GBM who had disease progression following standard surgical treatment and concomitant chemoradiotherapy, and was found to have sarcomatous transformation after initiation of TTF therapy with bevacizumab. Upon tumor progression, repeat surgical resection revealed transformation into a GFAP-negative, reticulin-positive sarcoma with rhabdomyoid features...
March 17, 2017: CNS Oncology
https://www.readbyqxmd.com/read/28001091/treatment-options-for-recurrent-high-grade-gliomas
#19
REVIEW
Harjus S Birk, Seunggu J Han, Nicholas A Butowski
High-grade gliomas are aggressive brain tumors encompassing Grade III and IV classifications. Of these, glioblastoma (GB) is the most malignant with a high rate of recurrence after initial resection. Although standard treatment does exist for newly diagnosed GBs, therapeutic strategies for recurrent GB are less solidified. However, mounting evidence describes the role of re-resection, bevacizumab, chemotherapy, targeted molecular therapies, immunotherapeutic approaches and radiotherapy in recurrent GB management...
January 2017: CNS Oncology
https://www.readbyqxmd.com/read/28001090/recent-technological-advances-in-pediatric-brain-tumor-surgery
#20
REVIEW
Bassel Zebian, Francesco Vergani, José Pedro Lavrador, Soumya Mukherjee, William John Kitchen, Vita Stagno, Christos Chamilos, Benedetta Pettorini, Conor Mallucci
X-rays and ventriculograms were the first imaging modalities used to localize intracranial lesions including brain tumors as far back as the 1880s. Subsequent advances in preoperative radiological localization included computed tomography (CT; 1971) and MRI (1977). Since then, other imaging modalities have been developed for clinical application although none as pivotal as CT and MRI. Intraoperative technological advances include the microscope, which has allowed precise surgery under magnification and improved lighting, and the endoscope, which has improved the treatment of hydrocephalus and allowed biopsy and complete resection of intraventricular, pituitary and pineal region tumors through a minimally invasive approach...
January 2017: CNS Oncology
journal
journal
47537
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"